148 related articles for article (PubMed ID: 36576222)
1. Citrus nutraceutical eriocitrin and its metabolites are partial agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a molecular docking and molecular dynamics study.
Gangadhariah M; Pardhi T; Ravilla J; Chandra S; Singh SA
J Biomol Struct Dyn; 2023; 41(21):11373-11393. PubMed ID: 36576222
[TBL] [Abstract][Full Text] [Related]
2. Computational investigation of phytochemicals from
Omoboyowa DA; Singh G; Fatoki JO; Oyeneyin OE
J Biomol Struct Dyn; 2023; 41(12):5568-5582. PubMed ID: 35773777
[TBL] [Abstract][Full Text] [Related]
3. Identification and antioxidant activity of flavonoid metabolites in plasma and urine of eriocitrin-treated rats.
Miyake Y; Shimoi K; Kumazawa S; Yamamoto K; Kinae N; Osawa T
J Agric Food Chem; 2000 Aug; 48(8):3217-24. PubMed ID: 10956094
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Biodistribution of Eriocitrin in Rats.
Ferreira PS; Manthey JA; Nery MS; Cesar TB
J Agric Food Chem; 2021 Feb; 69(6):1796-1805. PubMed ID: 33533607
[TBL] [Abstract][Full Text] [Related]
5. Eriocitrin: A review of pharmacological effects.
Yao L; Liu W; Bashir M; Nisar MF; Wan CC
Biomed Pharmacother; 2022 Oct; 154():113563. PubMed ID: 35987162
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.
Gee VM; Wong FS; Ramachandran L; Sethi G; Kumar AP; Yap CW
J Comput Aided Mol Des; 2014 Nov; 28(11):1143-51. PubMed ID: 25168706
[TBL] [Abstract][Full Text] [Related]
7. Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPARγ).
Wang J; Wang B; Zhang Y
J Biomol Struct Dyn; 2020 Feb; 38(2):398-409. PubMed ID: 31025599
[TBL] [Abstract][Full Text] [Related]
8. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
[TBL] [Abstract][Full Text] [Related]
9. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of peroxisome proliferator-activated receptor gamma (PPARγ) transactivation by hesperetin glucuronides is distinct from that by a thiazolidine-2,4-dione agent.
Gamo K; Shiraki T; Matsuura N; Miyachi H
Chem Pharm Bull (Tokyo); 2014; 62(5):491-3. PubMed ID: 24789933
[TBL] [Abstract][Full Text] [Related]
11. Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties.
Muralikumar S; Vetrivel U; Narayanasamy A; N Das U
Lipids Health Dis; 2017 Jan; 16(1):17. PubMed ID: 28109294
[TBL] [Abstract][Full Text] [Related]
12. Exploring Dual Agonists for PPARα/γ Receptors using Pharmacophore Modeling, Docking Analysis and Molecule Dynamics Simulation.
Ding TT; Liu YY; Zhang LM; Shi JR; Xu WR; Li SY; Cheng XC
Comb Chem High Throughput Screen; 2022; 25(9):1450-1461. PubMed ID: 34182904
[TBL] [Abstract][Full Text] [Related]
13. Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.
Hiramitsu M; Shimada Y; Kuroyanagi J; Inoue T; Katagiri T; Zang L; Nishimura Y; Nishimura N; Tanaka T
Sci Rep; 2014 Jan; 4():3708. PubMed ID: 24424211
[TBL] [Abstract][Full Text] [Related]
14.
Feng XY; Ding TT; Liu YY; Xu WR; Cheng XC
J Biomol Struct Dyn; 2021 Mar; 39(5):1853-1864. PubMed ID: 32189570
[TBL] [Abstract][Full Text] [Related]
15. Molecular Modeling Study for the Design of Novel Peroxisome Proliferator-Activated Receptor Gamma Agonists using 3D-QSAR and Molecular Docking.
Jian Y; He Y; Yang J; Han W; Zhai X; Zhao Y; Li Y
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473866
[TBL] [Abstract][Full Text] [Related]
16. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
17. Polyacetylenes from Notopterygium incisum--new selective partial agonists of peroxisome proliferator-activated receptor-gamma.
Atanasov AG; Blunder M; Fakhrudin N; Liu X; Noha SM; Malainer C; Kramer MP; Cocic A; Kunert O; Schinkovitz A; Heiss EH; Schuster D; Dirsch VM; Bauer R
PLoS One; 2013; 8(4):e61755. PubMed ID: 23630612
[TBL] [Abstract][Full Text] [Related]
18. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review.
Wang L; Waltenberger B; Pferschy-Wenzig EM; Blunder M; Liu X; Malainer C; Blazevic T; Schwaiger S; Rollinger JM; Heiss EH; Schuster D; Kopp B; Bauer R; Stuppner H; Dirsch VM; Atanasov AG
Biochem Pharmacol; 2014 Nov; 92(1):73-89. PubMed ID: 25083916
[TBL] [Abstract][Full Text] [Related]
19. Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors -α/γ dual agonists for treatment of metabolic disorders.
Nath V; Agrawal R; Kumar V
J Biomol Struct Dyn; 2020 Feb; 38(2):511-523. PubMed ID: 30767625
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations.
Liu X; Jing Z; Jia WQ; Wang SQ; Ma Y; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Aug; 36(11):2988-3002. PubMed ID: 28853334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
